Riechelmann, R. P. Et Al. 2019. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). CLINICAL COLORECTAL CANCER , vol.18, no.3 , 183-194.

Riechelmann, R. P., Srimuninnimit, V., Bordonaro, R., Kavan, P., Di Bartolomeo, M., Maiello, E., ... ÇİÇİN, İ.(2019). Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). CLINICAL COLORECTAL CANCER , vol.18, no.3, 183-194.

Riechelmann, Rachel Et Al. "Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)," CLINICAL COLORECTAL CANCER , vol.18, no.3, 183-194, 2019

Riechelmann, Rachel P. Et Al. "Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)." CLINICAL COLORECTAL CANCER , vol.18, no.3, pp.183-194, 2019

Riechelmann, R. P. Et Al. (2019) . "Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)." CLINICAL COLORECTAL CANCER , vol.18, no.3, pp.183-194.

@article{article, author={Rachel P. Riechelmann Et Al. }, title={Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)}, journal={CLINICAL COLORECTAL CANCER}, year=2019, pages={183-194} }